Table 2. Matrix of Bayesian NMA Resultsa.
| Measure | Estimate vs CMM |
|---|---|
| Proportion of patients achieving ≥50% pain reduction in back b | |
| Conventional SCS, OR (95% CrI) | 3.00 (1.49 to 6.72)c |
| Novel SCS, OR (95% CrI) | 8.76 (3.84 to 22.31)c |
| DIC | 14.07 |
| Studies in the network, No. | 5 |
| Total sample size, No. | 683 |
| Proportion of patients achieving ≥50% pain reduction in leg d | |
| Conventional SCS, OR (95% CrI) | 6.93 (0.67 to 49.35)e |
| Novel SCS, OR (95% CrI) | 10.13 (0.45 to 129.31)e |
| DIC | 26.15 |
| Studies in the network, No. | 7 |
| Total sample size, No. | 831 |
| Pain intensity in back b | |
| Conventional SCS, MD (95% CrI) | −1.17 (−1.64 to −0.70)c |
| Novel SCS, MD (95% CrI) | −2.34 (−2.96 to −1.73)c |
| DIC | 23.87 |
| Studies in the network, No. | 6 |
| Total sample size, No. | 738 |
| Pain intensity in leg d | |
| Conventional SCS, MD (95% CrI) | −2.89 (−4.03 to −1.81)c |
| Novel SCS, MD (95% CrI) | −4.01 (−5.31 to −2.75)c |
| DIC | 37.98 |
| Studies in the network, No. | 10 |
| Total sample size, No. | 1014 |
| EQ-5D Index score b | |
| Conventional SCS, MD (95% CrI) | 0.15 (0.09 to 0.21)c |
| Novel SCS, MD (95% CrI) | 0.17 (0.13 to 0.21)c |
| DIC | 19.49 |
| Studies in the network, No. | 6 |
| Total sample size, No. | 700 |
| ODI b | |
| Conventional SCS, MD (95% CrI) | −7.10 (−10.91 to −3.36)c |
| Novel SCS, MD (95% CrI) | −4.98 (−10.78 to 0.62)e |
| DIC | 11.13 |
| Studies in the network, No. | 3 |
| Total sample size, No. | 367 |
Abbreviations: CMM, conventional medical management; CrI, Credible interval; DIC, deviance information criterion; EQ-5D, EuroQol-5 Dimensions; MD, mean difference; ODI, Oswestry Disability Index; OR, odds ratio; SCS, spinal cord stimulation.
a
Additional follow-up times are provided in eTable 9 in Supplement 1.
b
Fixed-effects model.
c
Favorability of SCS vs CMM and achieved superiority (statistical significance).
d
Random-effects model.
e
Did not achieve superiority (statistical significance).